Q2 2023 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2023-08-14 · accession 0000950123-23-007696
$178.5M
Reported value
12
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76029N106 | REPL | Replimune Group | $69.7M | 39.0% | 3,001,319 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio | $27.1M | 15.2% | 15,072,340 | Common | SOLE |
| 02083G100 | NVLSEUR | Alpine Immune Sciences | $20.9M | 11.7% | 2,029,580 | Common | SOLE |
| 61775R105 | MORFUSD | Morphic Holding | $17.8M | 9.95% | 309,846 | Common | SOLE |
| 45175G108 | — | Ikena Oncology | $14.8M | 8.27% | 2,249,123 | Common | SOLE |
| 88369M101 | — | Theseus Pharmaceuticals | $6.6M | 3.72% | 711,479 | Common | SOLE |
| 50107A104 | KRON1USD | Kronos Bio | $6.6M | 3.68% | 3,818,283 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $5.0M | 2.82% | 843,750 | Common | SOLE |
| 85209E109 | — | Spruce Biosciences | $4.6M | 2.60% | 2,161,022 | Common | SOLE |
| 4525EP101 | VTLUSD | Immunic Inc | $4.5M | 2.51% | 1,788,160 | Common | SOLE |
| 87184Q206 | SYRS | Syros Pharmaceuticals | $791,500 | 0.44% | 251,270 | Common | SOLE |
| 81726A100 | — | Senti Biosciences, Inc. | $122,762 | 0.07% | 195,792 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.